Controversies in Treating Early HR-Positive Breast Cancer

December 14, 2017

This video reviews controversies in the treatment of early-stage hormone receptor (HR)-positive breast cancer.

In this video, Vered Stearns, MD, of Johns Hopkins School of Medicine in Baltimore, Maryland, reviews controversies in the treatment of early-stage hormone receptor (HR)-positive breast cancer.

Stearns gave a presentation on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.